ORCID Profile
0000-0001-8488-5245
Current Organisation
Monash University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Frontiers Media SA
Date: 27-05-2019
Publisher: Springer Science and Business Media LLC
Date: 05-03-2021
Publisher: Medknow
Date: 2020
Publisher: Elsevier BV
Date: 12-2020
Publisher: Elsevier BV
Date: 2019
DOI: 10.1016/J.DRUDIS.2018.10.001
Abstract: Human induced pluripotent stem cells (hiPSCs) enable in vitro high-throughput pharmacological screening assays of diseased tissue. Together with recent genome-wide association studies (GWAS), hiPSCs enable the identification of key mutations for the development of effective treatments based on precise drugs. In concert with CRISPR/Cas9 systems, hiPSC technology can reveal therapeutic targets in metabolic disorders. The ex vivo CRISPR correction of autologous patient-derived hiPSCs has led to the development of replacement cell therapies, providing better patient prognoses.
Publisher: MDPI AG
Date: 04-03-2020
DOI: 10.3390/MOLECULES25051150
Abstract: Human induced pluripotent stem cells (hiPSCs) have transformed conventional drug discovery pathways in recent years. In particular, recent advances in hiPSC biology, including organoid technologies, have highlighted a new potential for neural drug discovery with clear advantages over the use of primary tissues. This is important considering the financial and social burden of neurological health care worldwide, directly impacting the life expectancy of many populations. Patient-derived iPSCs-neurons are invaluable tools for novel drug-screening and precision medicine approaches directly aimed at reducing the burden imposed by the increasing prevalence of neurological disorders in an aging population. 3-Dimensional self-assembled or so-called ‘organoid’ hiPSCs cultures offer key advantages over traditional 2D ones and may well be gamechangers in the drug-discovery quest for neurological disorders in the coming years.
Publisher: Elsevier BV
Date: 09-2020
Location: Mexico
Location: Mexico
No related grants have been discovered for Jose Agustin Cota-Coronado.